Age‐related characteristics of gastric carcinoma in young and elderly patients

The clinicopathologic features of young and elderly patients with gastric carcinoma have been analyzed.

[1]  D. Carson,et al.  Cancer progression and p53 , 1995, The Lancet.

[2]  K. Yamamoto,et al.  Studies on clinicopathological features of lung cancer patients with K-ras/p53 gene alterations: comparison between younger and older groups. , 1995, Oncology.

[3]  Y. Maehara,et al.  A tumour-associated cell-surface glycoprotein accompanying p53 overexpression and higher growth potential for gastric cancer. , 1995, British Journal of Cancer.

[4]  Y. Maehara,et al.  Lymphatic invasion and potential for tumor growth and metastasis in patients with gastric cancer. , 1995, Surgery.

[5]  S. Syrjänen,et al.  Implications of the p53 tumor-suppressor gene in clinical oncology. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Y. Maehara,et al.  Growth pattern and p53 overexpression in patients with early gastric cancer , 1995, Cancer.

[7]  Y. Maehara,et al.  Gastric carcinoma in patients over 70 years of age , 1995, The British journal of surgery.

[8]  Y. Maehara,et al.  Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. , 1994, American journal of surgery.

[9]  A. Cuschieri,et al.  The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. , 1994, British Journal of Cancer.

[10]  K. Kobayashi,et al.  Comparative clinicopathologic features of early gastric cancer in young and older patients. , 1994, Surgery.

[11]  C. Begg,et al.  Factors associated with p53 nuclear accumulation in prostatic adenocarcinoma. , 1994, International journal of oncology.

[12]  Y. Maehara,et al.  Proliferative activity as a prognostic factor in Borrmann type 4 gastric carcinoma. , 1994, British Journal of Cancer.

[13]  A. Levine,et al.  The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. , 1994, British Journal of Cancer.

[14]  Y. Chung,et al.  Proliferating cell nuclear antigen labeling index of preoperative biopsy specimens in gastric carcinoma with special reference to prognosis , 1994, Cancer.

[15]  J. L. Frank,et al.  p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx , 1994, Cancer.

[16]  S. Wahl,et al.  p53 expression in precancerous gastric lesions: an immunohistochemical study of PAb 1801 monoclonal antibody on adenomatous and hyperplastic gastric polyps. , 1993, The American journal of gastroenterology.

[17]  Y. Maehara,et al.  Unregulated emissions from catalyst-equipped cars: EPA overview. , 1975, British Journal of Cancer.

[18]  Y. Maehara,et al.  Postgastrectomy anticancer chemotherapy for stage IV gastric cancer equally tolerable for patients under and over age 65. , 1993, Anticancer research.

[19]  D. Lane,et al.  Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. , 1992, Gastroenterology.

[20]  Y. Maehara,et al.  Risk factors which predict pattern of recurrence after curative surgery for patients with advanced gastric cancer. , 1992, Surgical oncology.

[21]  A. Ghosh,et al.  Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. , 1992, British Journal of Cancer.

[22]  Y. Maehara,et al.  Prophylactic lymph node dissection in patients with advanced gastric cancer promotes increased survival time , 1992, Cancer.

[23]  D. Lane,et al.  p53 expression and prognosis in gastric carcinoma , 1992, International journal of cancer.

[24]  Y. Maehara,et al.  Signet ring cell carcinoma of the stomach , 1992, Cancer.

[25]  Y. Maehara,et al.  Quality of life after gastrectomy in patients with carcinoma of the stomach , 1992, The British journal of surgery.

[26]  Y. Maehara,et al.  Pertinent risk factors and gastric carcinoma with synchronous peritoneal dissemination or liver metastasis. , 1991, Surgery.

[27]  Y. Maehara,et al.  Lower survival rate for patients under 30 years of age and surgically treated for gastric carcinoma. , 1991, British Journal of Cancer.

[28]  D. Lane,et al.  Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: An index of cell proliferation with evidence of deregulated expression in some, neoplasms , 1990, The Journal of pathology.

[29]  J. Hurwitz,et al.  Mechanism of elongation of primed DNA by DNA polymerase delta, proliferating cell nuclear antigen, and activator 1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Y. Maehara,et al.  Serum carcinoembryonic antigen level increases correlate with tumor progression in patients with differentiated gastric carcinoma following noncurative resection. , 1990, Cancer research.

[31]  D. Lane,et al.  Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. , 1990, The EMBO journal.

[32]  D. Lane,et al.  Monoclonal antibody analysis of the proliferating cell nuclear antigen (PCNA). Structural conservation and the detection of a nucleolar form. , 1990, Journal of cell science.

[33]  E. Tan,et al.  Flow cytometric multiparameter analysis of proliferating cell nuclear antigen/cyclin and Ki-67 antigen: a new view of the cell cycle. , 1990, Experimental cell research.

[34]  K. Inokuchi,et al.  [Intraoperative intraperitoneal administration of CDDP against gastric cancer with peritoneal dissemination]. , 1990, Gan to kagaku ryoho. Cancer & chemotherapy.

[35]  Rochelle L. Garcia,et al.  Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. , 1989, The American journal of pathology.

[36]  A. Iwashita,et al.  A clinicopathological study of synchronous multiple gastric cancer , 1989, The British journal of surgery.

[37]  R. Schwab,et al.  Cost-effectiveness and reimbursement issues in renal cell carcinoma. , 1989 .

[38]  Y. Maehara,et al.  Chemosensitivity differences between primary and metastatic lesions of clinical gastric cancer. , 1988, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[39]  D. Dent,et al.  Gastric Carcinoma in Young Adults , 1988, Annals of surgery.

[40]  A. Levine,et al.  Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life , 1988, Molecular and cellular biology.

[41]  K. Sugimachi,et al.  Results of resection of gastric cancer extending to adjacent organs , 1988, The British journal of surgery.

[42]  P. Correa,et al.  Gastric carcinoma in the young , 1987, Cancer.

[43]  D. M. Phillips,et al.  Cancer chemotherapy in the elderly. , 1987, American family physician.

[44]  M. Molaschi,et al.  Gastric cancer in the elderly: results of surgical treatment. , 1987, International surgery.

[45]  H. Beger,et al.  Total gastrectomy. A 15-year experience with particular reference to the patient over 70 years of age. , 1985, Archives of Surgery.

[46]  S. Andreola,et al.  Adequacy of Margins of Resection in Gastrectomy for Cancer , 1982, Annals of surgery.

[47]  Tanaki Kajitani,et al.  The general rules for the gastric cancer study in surgery and pathology , 1981, The Japanese journal of surgery.

[48]  S. Kawasaki.  [A clinicopathological study on upward intramural extension of cancer of the stomach (author's transl)]. , 1975, Fukuoka igaku zasshi = Hukuoka acta medica.